Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824

Novartis Foundation Symposium

Volumn 259, Issue , 2004, Pages 249-268

  Atadja, Peter ^a   Hsu, Meier ^a   Kwon, Paul ^a   Trogani, Nancy ^a   Bhalla, Kapil ^b   Remiszewski, Stacy ^a   Marmorstein, ^c   Marks, ^c   Castrono, ^c   Ott, ^c   Turner, ^c   Cohen, ^c  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; MOUSE; NUDE MOUSE; PROMOTER REGION;

ANIMALS; APOPTOSIS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED;

EID: 2942729947     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (27)

1. Boivin AJ, Momparler LF, Hurtubise A, Momparler RL 2002 Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 13:869-874
2. Corn PG, Kuerbitz SJ, van Noesel MM et al 1999 Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 59:3352-3356
3. Domann FE, Rice JC, Hendrix MJ, Futscher BW 2000 Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 85:805-810
4. Fournel M, Trachy-Bourget MC, Yan PT et al 2002 Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 62:4325-4330
5. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S 2001 Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 98:87-92
6. Gasco M, Sullivan A, Repellin C et al 2002 Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene 21:1876-1881
7. Greenberg VL, Williams JM, Cogswell JP, Mendenhall M, Zimmer SG 2001 Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 11:315-325
8. Han JW, Ahn SH, Park SH et al 2000 Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 60:6068-6074
9. Jaboin J, Wild J, Hamidi H et al 2002 MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62:6108-6115
10. Kim YB, Ki SW, Yoshida M, Horinouchi S 2000 Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J Antibiot (Tokyo) 53:1191-1200
11. Lavelle D, Chen YH, Hankewych M, DeSimone J 2001 Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 68:170-178
12. Marks PA, Richon VM, Rifkind RA 2000 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216
13. Richon VM, Zhou X, Rifkind RA, Marks PA 2001 Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (saha) for the treatment of cancers. Blood Cells Mol Dis 27:260-264
14. Saito A, Yamashita T, Mariko Y et al 1999 A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96:4592-4597
15. Sambucetti LC, Fischer DD, Zabludoff S et al 1999 Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274:34940-34947
16. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R 2002 Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 62:3698-3701
17. Sharpless NE, Bardeesy N, Lee KH et al 2001 Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413:86-91
18. Shinagawa T, Nomura T, Colmenares C, Ohira M, Nakagawara A, Ishii S 2001 Increased susceptibility to tumorigenesis of ski-deficient heterozygous mice. Oncogene 20:8100-8108
19. Sowa Y, Orita T, Minamikawa S et al 1997 Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241:142-150
20. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, Ford CD 2002 Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 1:1181-1190
21. Struhl K 1998 Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12:599-606
22. Suzuki T, Ando T, Tsuchiya K 1999 Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42:3001-3003
23. Suzuki T, Yokozaki H, Kuniyasu H et al 2000 Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 88:992-997
24. van Engeland M, Roemen GM, Brink M et al 2002 K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 21:3792-3795
25. Won J, Yim J, Kim TK 2002 Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J Biol Chem 277:38230-38238
26. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T 2002 Frequent epigenetic silencing of the p16 gene in non-small cell lung cancers of tobacco smokers. Jpn J Cancer Res 93:1107-1113
27. Yu X, Guo ZS, Marcu MG et al 2002 Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells of depsipeptide FR901228. J Natl Cancer Inst 94:504-513